Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)
Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of giving erlotinib and dovitinib
together to treat patients with metastatic non-small cell lung cancer. Erlotinib blocks the
epidermal growth factor receptor (EGFR) and has known activity in non-small cell lung cancer
and dovitinib blocks the fibroblast growth factor receptor (FGFR) and other targets which may
be important to treat lung cancer. The combination of both drugs may work better than either
drug alone, but may also have increased side effects. This trial will look at the side
effects of combining the drugs and look for how effective the combination may be.